國立虎尾科技大學 |

The basics of cancer immunotherapy

紀錄類型:	書目-語言資料,印刷品 : Monograph/item
正題名/作者:	The basics of cancer immunotherapy/ edited by Haidong Dong, Svetomir N. Markovic.
其他作者:	Markovic, Svetomir N.
出版者:	Cham :Springer International Publishing : : 2024.,
面頁冊數:	xiii, 221 p. :ill., digital ; : 24 cm.;
Contained By:	Springer Nature eBook
標題:	Patient Education. -
電子資源:	https://doi.org/10.1007/978-3-031-59475-5
ISBN:	9783031594755

The basics of cancer immunotherapy
The basics of cancer immunotherapy[electronic resource] /edited by Haidong Dong, Svetomir N. Markovic. - Second edition. - Cham :Springer International Publishing :2024. - xiii, 221 p. :ill., digital ;24 cm.

The basic concepts in cancer immunology and immunotherapy -- Immune checkpoint inhibitors in oncology -- Bi-specific, T cell engaging antibodies including Tebentifusp -- Cell therapy for cancer: CAR-T, TIL -- Viral immunotherapy strategies in clinical practice: TVEC -- Chemotherapy for resistant cancer to ICI -- Radio-immunotherapy for refractory cancers -- Immunotherapy for melanoma and skin cancer -- Immunotherapy for lung cancer -- Immunotherapy for breast cancer -- Immunotherapy for genitourinary malignancies -- Immunotherapy for gastrointestinal malignancies -- Immunotherapy in the solid organ transplant recipient -- Management of immune-related adverse events from immune checkpoint inhibitor therapy -- Resources for patients undergoing immune therapy for cancer -- Immunotherapy for head and neck cancer.

This comprehensively updated new edition provides patients and their physicians (especially non-oncologist healthcare providers) with a clear and concise introduction to cancer immunotherapy. Unlike traditional forms of cancer therapy, immunotherapy acts by boosting the patient's own immune system to fight cancer; immunotherapy's unique features make its management, monitoring and side-effects different from those of traditional cancer therapy. Especially novel are the side effects of cancer immunotherapy, necessitating greater awareness for both patients and physicians in order to minimize complications and maximize benefits. The patient-friendly and state-of-the-art knowledge presented in this book will inform patients and their care providers about the benefits and risks of cancer immunotherapy, and help them to understand how immunotherapy would control their unique disease. Researchers and academic professionals in the field of cancer immunotherapy will also find clear, useful information to help them communicate with patients and address unresolved issues. Key features include: Expertise. Editors and authors are scientists and oncologists specializing in cancer immunotherapy, involved in scientific discovery from the early stage of immune-checkpoint inhibitors to today's patient care. Their insights, expertise and experience guarantee high quality and authority in the science, medicine and practice of cancer immunotherapy. Patient-friendly. This book is written specifically for cancer patients considering or undergoing immunotherapy. As an educational tool, this book will help the reader to understand the underlying science, balance the risks and benefits based on both research and clinical facts, and make an informed decision regarding their treatment options. Disease Specificity. Cancer is a complicated disease involving multiple stages and pathology. Its response to immunotherapy is individualized and varies depending on cancer types. The authors' expertise in treating different types of cancers, including melanoma, lung, kidney, bladder, breast, and lymphoma, provides disease-specific insights in applying immunotherapy to each disease. State-of-the-Art. This edition has been comprehensively updated to reflect recent advances, including detailed coverage of the latest therapies like CAR-T, TIL, immune checkpoint inhibitors and bispecific T cell engaging antibodies, and dedicated chapters on breast cancer, solid organ transplant recipients, GI and genitourinary malignancies, and resistant cancer.

ISBN: 9783031594755

Standard No.: 10.1007/978-3-031-59475-5doiSubjects--Topical Terms:

962637
Patient Education.

LC Class. No.: RC271.I45 / B37 2024

Dewey Class. No.: 616.994061

The basics of cancer immunotherapy
LDR:04402nam a2200337 a 4500 001 1133543
003 DE-He213
005 20240705125453.0
006 m d
007 cr nn 008maaau
008 241213s2024 sz s 0 eng d
020 $a 9783031594755 $q (electronic bk.)
020 $a 9783031594748 $q (paper)
024 7 $a 10.1007/978-3-031-59475-5 $2 doi
035 $a 978-3-031-59475-5
040 $a GP $c GP
041 0 $a eng
050 4 $a RC271.I45 $b B37 2024
072 7 $a MJCM $2 bicssc
072 7 $a MED044000 $2 bisacsh
072 7 $a MJCM $2 thema
082 0 4 $a 616.994061 $2 23
090 $a RC271.I45 $b B311 2024
245 0 4 $a The basics of cancer immunotherapy $h [electronic resource] / $c edited by Haidong Dong, Svetomir N. Markovic.
250 $a Second edition.
260 $a Cham : $c 2024. $b Springer International Publishing : $b Imprint: Springer,
300 $a xiii, 221 p. : $b ill., digital ; $c 24 cm.
505 0 $a The basic concepts in cancer immunology and immunotherapy -- Immune checkpoint inhibitors in oncology -- Bi-specific, T cell engaging antibodies including Tebentifusp -- Cell therapy for cancer: CAR-T, TIL -- Viral immunotherapy strategies in clinical practice: TVEC -- Chemotherapy for resistant cancer to ICI -- Radio-immunotherapy for refractory cancers -- Immunotherapy for melanoma and skin cancer -- Immunotherapy for lung cancer -- Immunotherapy for breast cancer -- Immunotherapy for genitourinary malignancies -- Immunotherapy for gastrointestinal malignancies -- Immunotherapy in the solid organ transplant recipient -- Management of immune-related adverse events from immune checkpoint inhibitor therapy -- Resources for patients undergoing immune therapy for cancer -- Immunotherapy for head and neck cancer.
520 $a This comprehensively updated new edition provides patients and their physicians (especially non-oncologist healthcare providers) with a clear and concise introduction to cancer immunotherapy. Unlike traditional forms of cancer therapy, immunotherapy acts by boosting the patient's own immune system to fight cancer; immunotherapy's unique features make its management, monitoring and side-effects different from those of traditional cancer therapy. Especially novel are the side effects of cancer immunotherapy, necessitating greater awareness for both patients and physicians in order to minimize complications and maximize benefits. The patient-friendly and state-of-the-art knowledge presented in this book will inform patients and their care providers about the benefits and risks of cancer immunotherapy, and help them to understand how immunotherapy would control their unique disease. Researchers and academic professionals in the field of cancer immunotherapy will also find clear, useful information to help them communicate with patients and address unresolved issues. Key features include: Expertise. Editors and authors are scientists and oncologists specializing in cancer immunotherapy, involved in scientific discovery from the early stage of immune-checkpoint inhibitors to today's patient care. Their insights, expertise and experience guarantee high quality and authority in the science, medicine and practice of cancer immunotherapy. Patient-friendly. This book is written specifically for cancer patients considering or undergoing immunotherapy. As an educational tool, this book will help the reader to understand the underlying science, balance the risks and benefits based on both research and clinical facts, and make an informed decision regarding their treatment options. Disease Specificity. Cancer is a complicated disease involving multiple stages and pathology. Its response to immunotherapy is individualized and varies depending on cancer types. The authors' expertise in treating different types of cancers, including melanoma, lung, kidney, bladder, breast, and lymphoma, provides disease-specific insights in applying immunotherapy to each disease. State-of-the-Art. This edition has been comprehensively updated to reflect recent advances, including detailed coverage of the latest therapies like CAR-T, TIL, immune checkpoint inhibitors and bispecific T cell engaging antibodies, and dedicated chapters on breast cancer, solid organ transplant recipients, GI and genitourinary malignancies, and resistant cancer.
650 2 4 $a Patient Education. $3 962637
650 2 4 $a Cancer Therapy. $3 1389305
650 2 4 $a Immunology. $3 592892
650 2 4 $a Health Sciences. $3 1365910
650 0 $a Immunotherapy. $3 592896
650 0 $a Cancer $x Immunotherapy. $3 645557
700 1 $a Markovic, Svetomir N. $e editor. $3 1284150
700 1 $a Dong, Haidong. $e editor. $3 1284149
710 2 $a SpringerLink (Online service) $3 593884
773 0 $t Springer Nature eBook
856 4 0 $u https://doi.org/10.1007/978-3-031-59475-5
950 $a Biomedical and Life Sciences (SpringerNature-11642)